Kidney Cancer

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

Nivolumab plus cabozantinib yielded a median PFS of 16.4 months compared with 8.3 months from sunitinib alone in the first-line treatment of patients with advanced RCC.

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

Investigators of a phase 2 study will continue to assess long-term efficacy and quality-of-life outcomes in those who receive lenvatinib/pembrolizumab.

All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.

The program was brought together to discuss immunotherapy options for non–clear cell RCC in light of emerging clinical trial data and NCCN guidelines.

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.

A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.

Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.

Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.

Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.

“These data support the development of fianlimab plus cemiplimab combination therapy for patients with metastatic ccRCC,” said Miso Kim, MD, PhD.

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.

Various immunotherapy/TKI regimens were observed to determine the impact on survival in patients with metastatic renal cell carcinoma.